{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T13:40:59Z","timestamp":1791207659828,"version":"4.1.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"University of Pennsylvania \u201cImproved Therapies for MPS I Grant Program\u201d","award":["MPS I-11-001-01"],"award-info":[{"award-number":["MPS I-11-001-01"]}]},{"name":"NIH","award":["1R01GM094792"],"award-info":[{"award-number":["1R01GM094792"]}]}],"content-domain":{"domain":["mgmjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1016\/j.ymgme.2013.12.007","type":"journal-article","created":{"date-parts":[[2013,12,17]],"date-time":"2013-12-17T15:30:14Z","timestamp":1387294214000},"page":"374-381","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":48,"title":["Long-term nonsense suppression therapy moderates MPS I-H disease progression"],"prefix":"10.1016","volume":"111","author":[{"given":"Gwen","family":"Gunn","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanying","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valery","family":"Belakhov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeyakumar","family":"Kandasamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trenton R.","family":"Schoeb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timor","family":"Baasov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Bedwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim M.","family":"Keeling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2013.12.007_bb0005","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.pharmthera.2012.07.007","article-title":"Pharmaceutical therapies to recode nonsense mutations in inherited diseases","volume":"136","author":"Lee","year":"2012","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ymgme.2013.12.007_bb0215","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1542\/peds.2008-0416","article-title":"Mucopolysaccharidosis I: management and treatment guidelines","volume":"123","author":"Muenzer","year":"2009","journal-title":"Pediatrics"},{"key":"10.1016\/j.ymgme.2013.12.007_bb0220","first-page":"787","article-title":"Immunoquantification and enzyme kinetics of alpha-L-iduronidase in cultured fibroblasts from normal controls and mucopolysaccharidosis type I patients","volume":"50","author":"Ashton","year":"1992","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ymgme.2013.12.007_bb0020","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0925-4439(98)00046-5","article-title":"Genotype\u2013phenotype correlations in mucopolysaccharidosis type I using enzyme kinetics, immunoquantification and in vitro turnover studies","volume":"1407","author":"Bunge","year":"1998","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ymgme.2013.12.007_bb0225","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.molmed.2006.06.001","article-title":"Stop-codon read-through for patients affected by a lysosomal storage disorder","volume":"12","author":"Brooks","year":"2006","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.ymgme.2013.12.007_bb0030","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1093\/hmg\/10.3.291","article-title":"Gentamicin-mediated suppression of Hurler syndrome stop mutations restores a low level of alpha-L-iduronidase activity and reduces lysosomal glycosaminoglycan accumulation","volume":"10","author":"Keeling","year":"2001","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ymgme.2013.12.007_bb0230","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1097\/MOO.0b013e32833e05ec","article-title":"Cellular mechanisms of aminoglycoside ototoxicity","volume":"18","author":"Warchol","year":"2010","journal-title":"Curr. Opin. Otolaryngol. Head Neck Surg."},{"key":"10.1016\/j.ymgme.2013.12.007_bb0040","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/ki.2010.337","article-title":"New insights into the mechanism of aminoglycoside nephrotoxicity: an integrative point of view","volume":"79","author":"Lopez-Novoa","year":"2011","journal-title":"Kidney Int."},{"key":"10.1016\/j.ymgme.2013.12.007_bb0045","doi-asserted-by":"crossref","first-page":"3735","DOI":"10.1016\/j.bmc.2010.03.060","article-title":"Repairing faulty genes by aminoglycosides: development of new derivatives of geneticin (G418) with enhanced suppression of diseases-causing nonsense mutations","volume":"18","author":"Nudelman","year":"2010","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ymgme.2013.12.007_bb0050","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ymgme.2011.10.005","article-title":"The designer aminoglycoside NB84 significantly reduces glycosaminoglycan accumulation associated with MPS I-H in the Idua-W392X mouse","volume":"105","author":"Wang","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2013.12.007_bb0235","doi-asserted-by":"crossref","first-page":"e60478","DOI":"10.1371\/journal.pone.0060478","article-title":"Attenuation of nonsense-mediated mRNA decay enhances in vivo nonsense suppression","volume":"8","author":"Keeling","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ymgme.2013.12.007_bb0060","doi-asserted-by":"crossref","first-page":"112","DOI":"10.2353\/ajpath.2008.070564","article-title":"Mechanism of glycosaminoglycan-mediated bone and joint disease: implications for the mucopolysaccharidoses and other connective tissue diseases","volume":"172","author":"Simonaro","year":"2008","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ymgme.2013.12.007_bb0065","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00431-007-0635-4","article-title":"Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy","volume":"167","author":"Wraith","year":"2008","journal-title":"Eur. J. Pediatr."},{"key":"10.1016\/j.ymgme.2013.12.007_bb0240","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1093\/infdis\/124.Supplement_1.S214","article-title":"Pharmacologic evaluation of gentamicin in newborn infants","volume":"124","author":"McCracken","year":"1971","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ymgme.2013.12.007_bb0075","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1128\/AAC.32.7.1034","article-title":"Gentamicin penetration into cerebrospinal fluid in experimental Haemophilus influenzae meningitis","volume":"32","author":"Smith","year":"1988","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ymgme.2013.12.007_bb0245","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1126\/science.1174447","article-title":"A gene network regulating lysosomal biogenesis and function","volume":"325","author":"Sardiello","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.ymgme.2013.12.007_bb0085","doi-asserted-by":"crossref","first-page":"e35787","DOI":"10.1371\/journal.pone.0035787","article-title":"Neuropathology in mouse models of mucopolysaccharidosis type I, IIIA and IIIB","volume":"7","author":"Wilkinson","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ymgme.2013.12.007_bb0090","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1073\/pnas.252784899","article-title":"Activated microglia in cortex of mouse models of mucopolysaccharidoses I and IIIB","volume":"100","author":"Ohmi","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ymgme.2013.12.007_bb0095","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1203\/01.pdr.0000190579.24054.39","article-title":"Cardiac functional and histopathologic findings in humans and mice with mucopolysaccharidosis type I: implications for assessment of therapeutic interventions in hurler syndrome","volume":"59","author":"Braunlin","year":"2006","journal-title":"Pediatr. Res."},{"key":"10.1016\/j.ymgme.2013.12.007_bb0100","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.bbmt.2008.01.009","article-title":"The clinical outcome of Hurler syndrome after stem cell transplantation","volume":"14","author":"Aldenhoven","year":"2008","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.ymgme.2013.12.007_bb0105","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.ymgme.2009.08.002","article-title":"Characterization of an MPS I-H knock-in mouse that carries a nonsense mutation analogous to the human IDUA-W402X mutation","volume":"99","author":"Wang","year":"2010","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2013.12.007_bb0110","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/s00380-007-1013-x","article-title":"The mild form of mucopolysaccharidosis type I (Scheie syndrome) is associated with increased ascending aortic stiffness","volume":"23","author":"Nemes","year":"2008","journal-title":"Heart Vessels"},{"key":"10.1016\/j.ymgme.2013.12.007_bb0115","first-page":"524","article-title":"Gender-related dimorphism in aortic insufficiency in murine mucopolysaccharidosis type I","volume":"18","author":"Tolar","year":"2009","journal-title":"J. Heart Valve Dis."},{"key":"10.1016\/j.ymgme.2013.12.007_bb0120","first-page":"85","article-title":"Cartilage and chondrocyte pathology in the mucopolysaccharidoses: the role of glycosaminoglycan-mediated inflammation","volume":"3","author":"Simonaro","year":"2010","journal-title":"J. Pediatr. Rehab. Med."},{"key":"10.1016\/j.ymgme.2013.12.007_bb0125","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s10545-012-9522-x","article-title":"Assessment of bone dysplasia by micro-CT and glycosaminoglycan levels in mouse models for mucopolysaccharidosis type I, IIIA, IVA, and VII","volume":"36","author":"Rowan","year":"2013","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2013.12.007_bb0130","doi-asserted-by":"crossref","first-page":"2053","DOI":"10.2353\/ajpath.2009.090211","article-title":"Glycosaminoglycan-mediated loss of cathepsin K collagenolytic activity in MPS I contributes to osteoclast and growth plate abnormalities","volume":"175","author":"Wilson","year":"2009","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.ymgme.2013.12.007_bb0135","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2165\/00003088-200948020-00002","article-title":"Penetration of antibacterials into bone: pharmacokinetic, pharmacodynamic and bioanalytical considerations","volume":"48","author":"Landersdorfer","year":"2009","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ymgme.2013.12.007_bb0140","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.brainres.2007.10.036","article-title":"Progression of multiple behavioral deficits with various ages of onset in a murine model of Hurler syndrome","volume":"1188","author":"Pan","year":"2008","journal-title":"Brain Res."},{"key":"10.1016\/j.ymgme.2013.12.007_bb0145","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.bbr.2008.03.024","article-title":"Open field locomotor activity and anxiety-related behaviors in mucopolysaccharidosis type IIIA mice","volume":"191","author":"Lau","year":"2008","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.ymgme.2013.12.007_bb0150","doi-asserted-by":"crossref","first-page":"e772","DOI":"10.1371\/journal.pone.0000772","article-title":"Development of sensory, motor and behavioral deficits in the murine model of Sanfilippo syndrome type B","volume":"2","author":"Heldermon","year":"2007","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ymgme.2013.12.007_bb0155","first-page":"1","article-title":"The 6-minute walk test and other endpoints in Duchenne muscular dystrophy: longitudinal natural history observations over 48weeks from a multicenter study","author":"McDonald","year":"2013","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.ymgme.2013.12.007_bb0250","doi-asserted-by":"crossref","first-page":"D887","DOI":"10.1093\/nar\/gkr1061","article-title":"Mouse phenome database (MPD)","volume":"40","author":"Maddatu","year":"2012","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymgme.2013.12.007_bb0165","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.ymgme.2013.04.023","article-title":"Does early use of enzyme replacement therapy alter the natural history of mucopolysaccharidosis I? Experience in three siblings","volume":"109","author":"Laraway","year":"2013","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2013.12.007_bb0255","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/1750-1172-6-55","article-title":"Enzyme replacement therapy and\/or hematopoietic stem cell transplantation at diagnosis in patients with mucopolysaccharidosis type I: results of a European consensus procedure","volume":"6","author":"de Ru","year":"2011","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2013.12.007_bb0175","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.arcped.2007.08.026","article-title":"Hurler syndrome. Early diagnosis and successful enzyme replacement therapy: a new therapeutic approach. Case report","volume":"15","author":"Dupont","year":"2008","journal-title":"Arch. Pediatr."},{"key":"10.1016\/j.ymgme.2013.12.007_bb0180","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ymgme.2010.06.020","article-title":"Early versus late treatment of spinal cord compression with long-term intrathecal enzyme replacement therapy in canine mucopolysaccharidosis type I","volume":"101","author":"Dickson","year":"2010","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2013.12.007_bb0260","doi-asserted-by":"crossref","first-page":"60ra89","DOI":"10.1126\/scitranslmed.3001380","article-title":"Replacing the enzyme alpha-L-iduronidase at birth ameliorates symptoms in the brain and periphery of dogs with mucopolysaccharidosis type I","volume":"2","author":"Dierenfeld","year":"2010","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymgme.2013.12.007_bb0190","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1128\/CMR.00007-10","article-title":"Penetration of drugs through the blood-cerebrospinal fluid\/blood\u2013brain barrier for treatment of central nervous system infections","volume":"23","author":"Nau","year":"2010","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.ymgme.2013.12.007_bb0195","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nm0496-467","article-title":"Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations","volume":"2","author":"Howard","year":"1996","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymgme.2013.12.007_bb0200","doi-asserted-by":"crossref","first-page":"3861","DOI":"10.1016\/0006-2952(82)90303-3","article-title":"Mechanism of aminoglycoside-induced lysosomal phospholipidosis: in vitro and in vivo studies with gentamicin and amikacin","volume":"31","author":"Laurent","year":"1982","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ymgme.2013.12.007_bb0205","doi-asserted-by":"crossref","first-page":"4612","DOI":"10.1128\/AAC.00965-08","article-title":"Interaction of aminoglycosides with human mitochondrial 12S rRNA carrying the deafness-associated mutation","volume":"53","author":"Qian","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ymgme.2013.12.007_bb0210","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1002\/humu.20763","article-title":"A meta-analysis of nonsense mutations causing human genetic disease","volume":"29","author":"Mort","year":"2008","journal-title":"Hum. Mutat."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719213004216?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719213004216?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,4]],"date-time":"2019-08-04T21:26:43Z","timestamp":1564954003000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719213004216"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["S1096719213004216"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2013.12.007","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Long-term nonsense suppression therapy moderates MPS I-H disease progression","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2013.12.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}